Latham & Watkins Advises the Underwriters in Mirum Pharmaceuticals Public Offering

Mirum Pharmaceuticals, Inc, a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, has announced the pricing of its previously announced underwritten public offering of 3,750,000 shares of its common stock at a price to the public of US$20.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be US$75.0 million. 

Latham & Watkins LLP represents the underwriters in the offering with a life sciences capital markets team led by Bay Area partner Brian Cuneo, with Bay Area associate Alexander White and Orange County associate Eric Hanzich. Advice was also provided on intellectual property matters by Bay Area/San Diego partner Christopher Hazuka, with San Diego associates Brendan Haberle and Robert Yeh; on tax matters by Bay Area partner Grace Lee, with Washington, D.C. associate Eni Kassim; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Chad Jennings; and on benefits and compensation matters by Bay Area partner James Metz.